> Details

Parodi, Emilia; Rivetti, Elisa; Amendola, Giovanni; Bisogno, Gianni; Calabrese, Roberto; Farruggia, Piero; Giordano, Paola; Rosaria Matarese, Sofia Maria; Nardi, Margherita; Nobili, Bruno; Notarangelo, Lucia D.; Russo, Giovanna; Vimercati, Chiara; Zecca, Marco; De Mattia, Domenico; Ramenghi, Ugo

Long‐term follow‐up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Long‐term follow‐up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response
  • Contributor: Parodi, Emilia; Rivetti, Elisa; Amendola, Giovanni; Bisogno, Gianni; Calabrese, Roberto; Farruggia, Piero; Giordano, Paola; Rosaria Matarese, Sofia Maria; Nardi, Margherita; Nobili, Bruno; Notarangelo, Lucia D.; Russo, Giovanna; Vimercati, Chiara; Zecca, Marco; De Mattia, Domenico; Ramenghi, Ugo
  • imprint: Wiley, 2009
  • Published in: British Journal of Haematology
  • Language: English
  • DOI: 10.1111/j.1365-2141.2008.07487.x
  • ISSN: 0007-1048; 1365-2141
  • Origination:
  • Footnote:
  • Description: <jats:title>Summary</jats:title><jats:p>We report the long‐term follow‐up (median 39·5 months) of 49 paediatric patients (33 females and 16 males) with refractory symptomatic immune thrombocytopenic purpura (ITP) treated with rituximab. The overall response rate was 69% (34/49 patients). Twenty‐one responders had a platelet count &gt;50 × 10<jats:sup>9</jats:sup>/l at a median 20·2 months from treatment. Kaplan–Meier analysis showed a probability of relapse‐free survival (RFS) of 60% at 36 months from the first rituximab infusion. The number of infusions and a previous splenectomy did not influence overall response rate. Patients who achieved complete response were significantly older at diagnosis and first rituximab infusion than partial responders (<jats:italic>P</jats:italic> = 0·027). Older children displayed a significantly greater probability of sustained response (RFS) at 36 months than younger children (88·9% vs. 56·7%, <jats:italic>P</jats:italic> = 0·037). Earlier responses (within 20 d from treatment) were significantly associated with both complete (<jats:italic>P</jats:italic> = 0·004) and sustained response (<jats:italic>P</jats:italic> = 0·002). Only mild and transient side‐effects were observed in 9/49 children; no major infections nor delayed toxicities were recorded during the follow‐up.</jats:p>
  • Access State: Open Access